Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
"Maji" returns to the starting point overnight, faces further partial liquidation at dawn, with a weekly loss of nearly $4 million

"Maji" returns to the starting point overnight, faces further partial liquidation at dawn, with a weekly loss of nearly $4 million

BlockBeatsBlockBeats2026/04/30 01:12
Show original

BlockBeats News, April 30, according to monitoring by Hyperinsight, as the market pulled back again, "Maji" returned to its starting point overnight, with unrealized profits over the past week turning into unrealized losses. The current unrealized loss is 3.94 million US dollars.


In terms of operations, during the early hours when the market was declining, Maji urgently reduced a large number of ETH and BTC long positions. However, amid the rapid drop, some positions were still forcibly liquidated. Afterwards, within the past two hours, additional positions were reopened.


After this decline, the total position value of "Maji" fell to 29.06 million US dollars. The liquidation price for ETH holdings is 2,188 US dollars, and for BTC holdings it is 72,143.1 US dollars.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage